Explore

Reuters Reuters
Analysis-Obesity battle heats up again as Novo claws way back into race with Lilly

Analysis-Obesity battle heats up again as Novo claws way back into race with Lilly

By Maggie Fick and Bhanvi Satija LONDON, Aug 3 - Novo Nordisk investors have found little cause for optimism during a bruising two-year period of profit warnings, leadership upheaval and a sliding share price as rival Eli Lilly streaked ahead. Now they may have reason for hope.
Trendline Trendline
SB1 Markets Recommends Buying Novo Nordisk Stock Ahead of Earnings Report

SB1 Markets Recommends Buying Novo Nordisk Stock Ahead of Earnings Report

SB1 Markets Recommends Buying Novo Nordisk Stock Ahead of Earnings Report
Reuters Reuters
Eli Lilly to offer early access to next-gen obesity drug to some patients

Eli Lilly to offer early access to next-gen obesity drug to some patients

By Sneha S K and Deena Beasley Aug 3 (Reuters) - Eli Lilly said on Monday it would allow a limited number of patients to have early access to its experimental obesity drug, retatrutide, before its U.S. FDA approval.
Reuters Reuters
AstraZeneca investors balk at prospect of $400 billion Bristol Myers pharma deal

AstraZeneca investors balk at prospect of $400 billion Bristol Myers pharma deal

By Maggie Fick LONDON, Aug 3 (Reuters) - AstraZeneca investors punished the pharmaceutical firm on Monday over reports of merger talks with U.S. rival Bristol Myers Squibb that could make one of the world's biggest drugmakers with a combined value of nearly $400 billion.
Trendline Trendline
Novo Nordisk Expands GLP-1 Drug Portfolio Amid Rising Market Competition

Novo Nordisk Expands GLP-1 Drug Portfolio Amid Rising Market Competition

Novo Nordisk Expands GLP-1 Drug Portfolio Amid Rising Market Competition
Reuters Reuters
AstraZeneca investors baulk at $400 billion Bristol Myers talks

AstraZeneca investors baulk at $400 billion Bristol Myers talks

By Maggie Fick LONDON, Aug 3 (Reuters) - AstraZeneca's shares fell sharply on Monday as investors baulked at reports of merger talks with Bristol Myers Squibb about forming what would become one of the world's biggest drugmakers with a combined value of nearly $400 billion.
TheStreet TheStreet
Morgan Stanley uncovers major Bristol Myers stock signals

Morgan Stanley uncovers major Bristol Myers stock signals

Bristol Myers Squibb (BMY) just gave investors a strong quarter and a bigger outlook. Morgan Stanley read the same report and kept its rating exactly where it was. (The source of much of this article is a Morgan Stanley report shared with me.) Morgan Stanley sees the stock falling to $40, well ...
Reuters Reuters
Pfizer beats earnings estimates, targets $2.5 billion in additional cost cuts

Pfizer beats earnings estimates, targets $2.5 billion in additional cost cuts

Aug 4 (Reuters) - Pfizer on Tuesday reported better-than-expected second-quarter results, boosted by strong demand for blood thinner Eliquis, and unveiled plans for an additional $2.5 billion in savings through its ongoing cost-cutting efforts.
TheStreet TheStreet
Novo Nordisk shares in hot water after disappointing trial

Novo Nordisk shares in hot water after disappointing trial

Investors who had hopes that Novo Nordisk (NVO) could succeed outside of weight-loss drugs were disappointed on Friday, July 31. The Danish drugmaker said its experimental heart drug Ziltivekimab failed the main goal of a large late-stage trial, and the stock fell fast. Novo has spent 2026 trying ...
Trendline Trendline
Eli Lilly Outperforms Novo Nordisk Amid Diverging Financial Strategies

Eli Lilly Outperforms Novo Nordisk Amid Diverging Financial Strategies

Eli Lilly Outperforms Novo Nordisk Amid Diverging Financial Strategies
Trendline Trendline
Novo Nordisk Faces Setback as Heart Drug Trial Fails to Meet Key Endpoint

Novo Nordisk Faces Setback as Heart Drug Trial Fails to Meet Key Endpoint

Novo Nordisk Faces Setback as Heart Drug Trial Fails to Meet Key Endpoint
Trendline Trendline
Novo Nordisk's IL-6 Inhibitor Fails in Phase 3 Cardiovascular Trial, Shares Drop

Novo Nordisk's IL-6 Inhibitor Fails in Phase 3 Cardiovascular Trial, Shares Drop

Novo Nordisk's IL-6 Inhibitor Fails in Phase 3 Cardiovascular Trial, Shares Drop